Market Access Capital discipline in biotech: Building enduring companies w... Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
Market Access Highlights from the UK’s December 2025 VPAG metrics Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.
Market Access For life sciences, it’s not only about when to bring on a GC... For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Market Access BIO-Europe Spring 2026: In conversation with Marjorie Sidhou... Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.